ReviewThe journal of allergy and clinical immunology. In practice2019
Controversies in Drug Allergy: Beta-Lactam Hypersensitivity Testing.
Review in The journal of allergy and clinical immunology. In practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Article
- Drug-induced anaphylaxis: Molecular pathophysiology, diagnosis, and management.Asia Pacific allergy · 2026Article
- Direct Single-Dose Drug-Provocation Test Is Safe for Delabelling Penicillin Low-Risk Reactions in Adults.Allergy · 2025Article
- Penicillin Allergy in China: Consequences of Inappropriate Skin Testing Practices and Policies.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- Is a Drug Allergy in a Patient's History Real? Our Experience with Diagnostic Drug Provocation Tests.Medicina (Kaunas, Lithuania) · 2025Article
- Urticaria-Like Hypersensitivity Reaction Following Botulinum Toxin Injection: A Case Report of Possible Interaction with β-Lactam Antibiotics.International medical case reports journal · 2025Article
- Impact of a pharmacist driven antimicrobial stewardship program on inpatient antibiotic consumption in a Chinese Tertiary Hospital: a 5-year retrospective study.Frontiers in medicine · 2025Article
- Narrative review of recent developments and the future of penicillin allergy de-labelling by non-allergists.npj antimicrobials and resistance · 2024Review
- Challenging dogmas: Intravenous versus oral beta-lactam antibiotic provocation tests.The World Allergy Organization journal · 2024Article
- Effectiveness analysis of a pharmacist-led intervention for orthopedic perioperative use of antibiotics: a retrospective cohort study.Frontiers in pharmacology · 2024Article
- Delabelling beta-lactam allergy.Frontiers in pharmacology · 2024Article
- Resensitization in suspected penicillin allergy.Allergy · 2023Article
- Approach for delabeling beta-lactam allergy in children.Frontiers in allergy · 2023Review
- Antibiotic Allergy De-Labeling: A Pathway against Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2022Review
- Negative impact of penicillin allergy labels on antibiotic use in hospitalized patients in Chinese Mainland.The World Allergy Organization journal · 2022Article
- Changes in Sensitization Patterns in the Last 25 Years in 619 Patients with Confirmed Diagnoses of Immediate Hypersensitivity Reactions to Beta-Lactams.Biomedicines · 2022Article
- Standards for practical intravenous rapid drug desensitization & delabeling: A WAO committee statement.The World Allergy Organization journal · 2022Review
- Immediate and Delayed Hypersensitivity Reactions to Beta-Lactam Antibiotics.Clinical reviews in allergy & immunology · 2022Review
- Patients with questionable penicillin (beta-lactam) allergy: Causes and solutions.Allergologie select · 2022Review
- Differences in beta-lactam and penicillin allergy: Beyond the West and focusing on Asia-Pacific.Frontiers in allergy · 2022Review
Corrections and comments
- Commented on by
- Erratum issuedCorrection.2019
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
All beta-lactam use is associated with a certain rate of adverse reactions. Many of these adverse reactions result in an allergy to the beta-lactam being entered into the patient's medical record. Unfortunately, only a small minority of these recorded allergies are clinically significant immunologically mediated drug hypersensitivity. An unconfirmed allergy to beta-lactams is a significant public health risk, because patients so labeled typically do not receive narrow-spectrum penicillins and cephalosporins when clinically indicated. The alternative antibiotics they receive result in poorer clinical outcomes, increased incidence of serious antibiotic-resistant infections, prolonged hospitalizations, and greater health care utilization. There is a wide variation in beta-lactam allergy incidence and prevalence around the world, based in part on the specific beta-lactams used and overused. There is a wide variation in specific protocols used to confirm current tolerance of beta-lactams and remove these inaccurate allergy reports. Harmonizing testing protocols, when possible, may lead to more widespread use of narrow-spectrum beta-lactams, when clinically indicated, and improve patient safety worldwide. Further research is needed to better understand the regional differences in reporting beta-lactam allergy as this relates to regional differences in beta-lactam use and overuse, the frequency of clinically significant immunologically mediated beta-lactam hypersensitivity, and the optimal testing strategies to confirm current tolerance, based on presenting clinical symptoms.
Indexed as
Identifiers
30245291What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.